JPWO2020065034A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020065034A5 JPWO2020065034A5 JP2021516939A JP2021516939A JPWO2020065034A5 JP WO2020065034 A5 JPWO2020065034 A5 JP WO2020065034A5 JP 2021516939 A JP2021516939 A JP 2021516939A JP 2021516939 A JP2021516939 A JP 2021516939A JP WO2020065034 A5 JPWO2020065034 A5 JP WO2020065034A5
- Authority
- JP
- Japan
- Prior art keywords
- fgfr3
- achondroplasia
- pharmaceutical composition
- bone disease
- dysplasia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 12
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 12
- 208000020084 Bone disease Diseases 0.000 claims 6
- 206010008723 Chondrodystrophy Diseases 0.000 claims 6
- 206010058314 Dysplasia Diseases 0.000 claims 6
- 208000008919 achondroplasia Diseases 0.000 claims 6
- 210000000845 cartilage Anatomy 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 208000009283 Craniosynostoses Diseases 0.000 claims 3
- 206010049889 Craniosynostosis Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- QADPYRIHXKWUSV-UHFFFAOYSA-N BGJ-398 Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=CC(N(C)C(=O)NC=2C(=C(OC)C=C(OC)C=2Cl)Cl)=NC=N1 QADPYRIHXKWUSV-UHFFFAOYSA-N 0.000 claims 2
- 231100000020 developmental retardation Toxicity 0.000 claims 2
- 230000001605 fetal effect Effects 0.000 claims 2
- 229950005712 infigratinib Drugs 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000007326 Muenke Syndrome Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306275.1 | 2018-09-28 | ||
| EP18306275 | 2018-09-28 | ||
| PCT/EP2019/076241 WO2020065034A1 (en) | 2018-09-28 | 2019-09-27 | Infigratinib for treatment of fgfr3-related skeletal diseases during pregnancy |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022502408A JP2022502408A (ja) | 2022-01-11 |
| JP2022502408A5 JP2022502408A5 (https=) | 2022-07-07 |
| JPWO2020065034A5 true JPWO2020065034A5 (https=) | 2022-07-07 |
| JP7390370B2 JP7390370B2 (ja) | 2023-12-01 |
Family
ID=63798918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021516939A Active JP7390370B2 (ja) | 2018-09-28 | 2019-09-27 | 妊娠中のｆｇｆｒ３関連骨疾患の処置ためのインフィグラチニブ |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20220040175A1 (https=) |
| EP (1) | EP3856187B1 (https=) |
| JP (1) | JP7390370B2 (https=) |
| ES (1) | ES3025795T3 (https=) |
| WO (1) | WO2020065034A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021250198A1 (en) * | 2020-06-11 | 2021-12-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of fgfr3-related cognitive deficit |
| CA3202267A1 (en) * | 2020-12-18 | 2022-06-23 | Riccardo Panicucci | Methods of treating achondroplasia |
| EP4452271A1 (en) * | 2021-12-20 | 2024-10-30 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Use of a fgfr3 tyrosine kinase inhibitor for the treatment of fgfr-related bone repair and bone formation impairments |
| JP2026507903A (ja) * | 2023-03-06 | 2026-03-06 | キューイーディー セラピューティクス，インコーポレイテッド | 骨格形成異常の治療方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9133328B2 (en) * | 2011-12-12 | 2015-09-15 | Sa Des Eaux Minerales D'evian Saeme | Plastic compositions and containers made thereof |
| WO2013088191A1 (en) * | 2011-12-12 | 2013-06-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3 |
-
2019
- 2019-09-27 JP JP2021516939A patent/JP7390370B2/ja active Active
- 2019-09-27 US US17/280,620 patent/US20220040175A1/en not_active Abandoned
- 2019-09-27 ES ES19778516T patent/ES3025795T3/es active Active
- 2019-09-27 EP EP19778516.5A patent/EP3856187B1/en active Active
- 2019-09-27 WO PCT/EP2019/076241 patent/WO2020065034A1/en not_active Ceased
-
2024
- 2024-02-28 US US18/589,498 patent/US20240285626A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021098728A5 (https=) | ||
| Fahmy | Cervical thymic cysts: their pathogenesis and relationship to branchial cysts | |
| BR9914360A (pt) | N-aralquilaminotetralinas como ligandos para oreceptor neuropeptìdeo yy5 | |
| JPWO2012147986A1 (ja) | 安定な医薬組成物 | |
| JP2022502408A5 (https=) | ||
| JP2004161667A (ja) | 生薬配合医薬組成物 | |
| JPWO2020065034A5 (https=) | ||
| CN100589817C (zh) | 治疗鸡痘的中药散剂及其制备方法 | |
| JPWO2012091090A1 (ja) | 解熱鎮痛組成物 | |
| JP3982889B2 (ja) | イブプロフェン含有医薬製剤 | |
| CN107519152A (zh) | 一种口腔溃疡膜及其制备方法 | |
| CN103705479B (zh) | 一种宠物用美洛昔康缓释片及其制备方法 | |
| CN105919967A (zh) | 一种盐酸阿考替胺制剂及其应用 | |
| CN110169976A (zh) | 含有腺苷a1受体激动剂的抗抑郁药物组合物及其应用 | |
| CN103041046B (zh) | 广东紫珠及其提取物在制备抗消化性溃疡药物中的应用 | |
| CN100594911C (zh) | 一种药物组合物及其用途 | |
| JP6804190B2 (ja) | 医薬組成物 | |
| JP6940264B2 (ja) | 止瀉剤組成物 | |
| LU507157B1 (en) | Medicated powder formula for treating oral ulcers and preparation method thereof | |
| JPH10175852A5 (https=) | ||
| JP2007137896A (ja) | イブプロフェン含有医薬製剤 | |
| CN116832082A (zh) | 一种潺槁树根皮提取物及其制备方法与在制备治疗和/或预防心血管疾病的药物中的应用 | |
| CN105920043A (zh) | 一种复方氨酚烷胺片及其制备方法 | |
| CN1730025A (zh) | 一种治疗胃炎、胃溃疡及十二指肠溃疡的药物组合物 | |
| CN101306007A (zh) | 依博素在制备治疗类风湿性关节炎的药物中的用途 |